Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gaming and Leisure Properties Inc. Common Stock (GLPI) vs Ionis Pharmaceuticals Inc. Common Stock (IONS) Price & Performance

Gaming and Leisure Properties Inc. Common StockTrade
Ionis Pharmaceuticals Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Gaming and Leisure Properties Inc. Common Stock vs Ionis Pharmaceuticals Inc. Common Stock — how do they compare? Gaming and Leisure Properties Inc. Common Stock trades at $38.13 (market cap $11.15B), while Ionis Pharmaceuticals Inc. Common Stock trades at $42.5 (market cap $7.04B). The key difference: Gaming and Leisure Properties Inc. Common Stock is the larger of the two by market cap, and Gaming and Leisure Properties Inc. Common Stock pays a 8.56% dividend while Ionis Pharmaceuticals Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gaming and Leisure Properties Inc. Common Stock for 0 Days and Ionis Pharmaceuticals Inc. Common Stock for 0 Days on average.

GLPIIONS
Market Cap
$11.15B$7.04B
Volume
1,865,4902,977,440
Sector
Real EstateHealth
52-Week High
$49.82$86.50
52-Week Low
$37.59$42.38
Typical Hold Time
0 Days0 Days
Enterprise Value
$19.21B$6.60B
Dividend Yield
8.56%—

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GLPI
100% Buy0% Sell
Avg holding period · 0 Days
IONS
100% Buy0% Sell
Avg holding period · 0 Days

About Gaming and Leisure Properties Inc. Common Stock

Gaming and Leisure Properties Inc. is a real estate investment trust that acquires, finances, and owns casino and gaming properties, which it leases to gaming operators under triple-net lease arrangements. It was the first publicly traded REIT focused on the gaming real estate sector in North America.

Read more on GLPI →

About Ionis Pharmaceuticals Inc. Common Stock

Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.

Read more on IONS →